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Altered densities of enteroendocrine cells play an important role in patients with irritable bowel syndrome (IBS). Uroguanylin
activates guanylate cyclase-C to regulate intestinal electrolyte and water transport. Aim. To quantify uroguanylin
immunoreactive cells density in the duodenum of diarrhea-predominant IBS (IBS-D) patients compared to controls and to
investigate the effect of fecal microbiota transplantation (FMT) on these cell densities. Method. Twelve patients with IBS-D
according to Rome III criteria were included. The cause was identified as post infectious (PI, n = 6) or idiopathic (n = 6). They
completed the IBS-symptom questionnaire before and 3 weeks after FMT. Thirty grams of fresh feces donated from healthy
relatives were diluted with 60ml normal saline and instilled via endoscope into the duodenum. Biopsies were taken from the
patients’ duodenum before and 3 weeks after FMT. Duodenal biopsies taken from eight healthy controls were also included. The
biopsies were immunostained for uroguanylin and quantified using computerized image analysis. Results. Uroguanylin
immunoreactive cells were found both in duodenal villi and crypts in both controls and IBS-D patients. The densities of
uroguanylin immunoreactive cells were significantly lower in the villi (P < 0:0001) and higher in the crypts (P < 0:0001) for the
patients than the controls. Following FMT, the densities of uroguanylin immunoreactive cells for the total group and idiopathic
subgroup decreased significantly in the duodenal crypts (P = 0:049 and 0.04, respectively) but not in the villi. No significant
changes were shown in the PI-IBS subgroups. The cells density in only the crypts correlated with diarrhea (r = 0:97, P = 0:001)
and bloating (r = –0:91, P = 0:01) in the PI-IBS subgroup before FMT and with abdominal pain (r = 0:63, P = 0:03) in the total
group of IBS-D patients after FMT. Conclusion. Altered uroguanylin immunoreactive cells density was found in IBS-D patients
compared to controls. Changes in these cells density following FMT correlated with IBS symptoms (diarrhea, bloating, and
abdominal pain).
1. Introduction
Irritable bowel syndrome (IBS) is a chronic disorder of the
gastrointestinal tract with an unclear cause and several con-
tributing factors such as diet [1], infections [2, 3], genetics
[4], gut microbiota [5, 6], and gut hormones [7, 8]. Interac-
tions of the above-mentioned contributing factors with each
other have certain effects on the gut-brain axis that may con-
tribute to the development of symptoms related to the gastro-
intestinal [9, 10] and nervous [11, 12] systems. Previous
publications have shown the effect of dietary changes on
the symptoms [1, 13–16], gut microbiota [17, 18], and enter-
oendocrine cells [19–21] in IBS patients. In addition, chang-
ing the composition of the gut microbiota through fecal
microbiota transplantation (FMT) had a positive clinical out-
come not only in cases of Clostridium difficile [22, 23] but
also in IBS [24–28].
The gut neuroendocrine system regulates all the functions
of the gastrointestinal tract and consists of enteroendocrine
cells and the enteric nervous system [29]. Enteroendocrine
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cells are specialized cells that spread among the intestinal epi-
thelial cells in both villi and crypts [29]. They have special-
ized microvilli that project into the gut lumen to act as
sensors for the luminal contents and respond to luminal
stimuli by releasing hormones that generally target other
parts of the digestive system [29]. The guanylin peptide fam-
ily includes guanylin, uroguanylin, lymphoguanylin, and
renoguanylin and is proposed to function as intestinal natri-
uretic peptides [30]. Uroguanylin, encoded by the GUCA2B
gene [31, 32], is a 16 amino acid peptide that is secreted by
duodenal and proximal small intestinal enterocytes [33].
Uroguanylin acts as an agonist of the guanylyl cyclase recep-
tor guanylate cyclase-C (GC-C) [34–36] by which its activa-
tion results in catalyzing the production of cyclic guanosine
monophosphate (cGMP) (Figure 1) [37], hence regulating a
variety of key processes such as chloride and bicarbonate
secretion [37–39], epithelial cell growth, intestinal barrier
integrity, and visceral sensitivity [39].
Newly published studies by our group [26, 28] showed
that using FMT in patients with diarrhea-predominant IBS
(IBS-D) improved their symptoms and changed their gut
microbiota profile. Using the same study cohort, the aims
of this study were to determine whether there is abnormality
in the density of uroguanylin immunoreactive cells in the
duodenum of IBS patients compared to healthy controls
(controls), to study the effect of changing the gut microbiota
through FMT on the density of these cells, and to find the
correlations between these cells and IBS symptoms (if any).
2. Methods
2.1. Patients, Donors, and Controls. Patients (n = 16) who
were referred to the outpatient clinic of gastroenterology,
Haukeland University Hospital, Bergen, Norway, met the
Rome III criteria for IBS, and scored >175 for the IBS-
Symptom Severity Scoring system (IBS-SSS) were included
in the current study.
Patients who had a history of inflammatory bowel dis-
eases, GI malignancy, blood in stool, oral thrush, dissemi-
nated lymphadenopathy, underwent abdominal surgery,
and pregnant or lactating women were excluded. In addi-
tion, the exclusion criteria included immunocompromised
patients or those taking immunosuppressive medications,
had history of opportunistic infections within 1 year, or
took probiotics or antibiotics within 1 month prior to fecal
transplantation.
Feces donors were healthy family members not com-
plaining of IBS and were 7 males and 9 females with an age
range of 20-55 (mean age 35) years. The exclusion criteria
for the donors were the same as for the patients.
Biopsy samples from a group of 12 healthy volunteers, 10
females and 2 males with an age range of 20-42 (mean age 39)
years, recruited at Stord Hospital, Stord, Norway, by adver-
tising in the local newspapers, were used as controls to study
duodenal uroguanylin immunoreactive cells.
The study was performed in accordance with the Decla-
ration of Helsinki [40] and was approved by the Regional
Committee for Medical and Health Research Ethics in West-
ern Norway (reference no.: 2013/1497). The current study
was registered at ClinicalTrials.gov (ID: NCT03333291). All
participants provided written informed consent. All the data
concerning uroguanylin immunoreactive cell density for the
current study are presented in this article.
2.2. Study Design. As previously explained in details [26], the
donors and patients underwent screening one week before
FMT and were physically examined and blood tested to
exclude contagious infectious agents for the donors (hepatitis
A, B, and C; HIV; Epstein-Barr virus; and cytomegalovirus)
and organic disorders for the patients according to previously
published recommendations [22, 41, 42]. Stool samples from
both donors and patients were examined for fecal calprotec-
tin and screened for bacteria, viruses, parasites, and eggs. The

















Figure 1: Activation cascade of binding of uroguanylin to guanylate cyclase-C receptor on the intestinal epithelial cell. Binding of uroguanylin
to guanylate cyclase-C results in receptor activation, catalyzing the production of cyclic guanosine monophosphate (cGMP). Cyclic GMP can
activate cGMP-dependent protein kinase II (PKGII) or inhibit the activity of a cyclic adenosine monophosphate- (cAMP-) specific
phosphodiesterase, PDE III, thereby crossactivating cAMP-dependent protein kinase (PKA). PKGII and PKA phosphorylate the cystic
fibrosis transmembrane conductance regulator or CFTR, increasing its chloride-secreting activity and preventing the absorption of sodium [37].
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and to report of any change in their life style or use of new
medications before the start or during the study.
2.3. FMT Procedure. Thirty grams of fresh feces collected
from the donors (<2 hours from production to donation)
were manually mixed with 60ml normal saline and sieved
for preparing fecal suspension without any hard particles
[22, 41, 42], on the transplantation day. After an overnight
fast, 60ml of fecal suspension followed by 60ml normal
saline were flushed only once through the endoscope into
the descending part of the patients’ duodenum. Tissue biop-
sies were taken from the descending part of the duodenum
before installation of feces and again after 3 weeks. Fecal sam-
ples were collected on the same day of FMT (before the pro-
cedure) and 3 weeks after FMT and sent for microbiota
analysis using the GA-map™ Dysbiosis Test (Genetic Analy-
sis AS, Oslo, Norway) as previously explained in details [26].
2.4. Questionnaires. The following questionnaires for IBS
symptom assessment were completed by the patients before
and 3 weeks after FMT: (a) IBS-Symptom Severity Scoring
system (IBS-SSS scores < 175 represent mild IBS symptoms,
175–300 represent moderate severity, > 300 represent severe
IBS) by which a decrease of 50 points correlates with improve-
ment in clinical symptoms [43] and (b) IBS-symptom ques-
tionnaire (IBS-SQ) which reports each of IBS symptoms
(nausea, bloating, abdominal pain, constipation, diarrhea,
and anorexia) using a severity scale from 0 to 10, where 0 =
no symptoms and 10 = severe symptoms [44, 45].
2.5. Gastroscopy and Immunohistochemistry. The patients
fasted overnight prior to undergoing a gastroscopy. During
the gastroscopy, four tissue biopsies were collected from
the descending part of the duodenum, distal to the papilla.
The biopsy samples were fixed in formaldehyde and embed-
ded in paraffin. The biopsies were cut into 3μm thick sec-
tions. Antigen retrieval was performed in the PT-Link®
system for 20 minutes at 98°C with the Dako® EnVision
FLEX Target retrieval buffer at pH6 (K8005; Dako, Jena,
Germany). Peroxidase blocking solution was used for 10
minutes. Thereafter, further blocking with 5% goat serum
(X0907; Dako) in 3% bovine serum albumin for 30 minutes
was performed. A one-hour incubation with a 1 : 50 dilution
of the primary polyclonal rabbit antibody to guanylate
cyclase type B was used (GUCA2B, no. LS-C371347, Life-
Span BioSciences Inc., Seattle, WA, USA). The secondary
EnVision HRP anti-rabbit (K4011; Dako) antibody was incu-
bated for 30 minutes. The slides were incubated with 3,3′-
diaminobenzidine (DAB) solution for 8 minutes followed
by counterstaining with hematoxylin.
2.6. Computerized Image Analysis. Uroguanylin immunore-
active cells density was quantified using a light microscope
with ×40 objective and a computer software Cell^B imaging
program (Olympus, Tokyo, Japan). By keeping the identity of
the slides concealed, the quantification was performed by
T.M. in 10 nonoverlapping fields. Each field (frame) of epi-
thelial cells represents a tissue area measured at 0.09mm2.
The density of uroguanylin immunoreactive cells in the duo-
denal villi was expressed as the number of cells/100 epithe-
lial cells and in duodenal crypts as the number of cells/mm2
of epithelium.
2.7. Gut Microbiota Analysis. The analysis was previously
described in details [26]. Briefly, GA-map™ Dysbiosis Test
is based on fecal homogenization and automated total bacte-
rial genomic DNA extraction using magnetic beads. Fifty-
four DNA probes were used to target bacterial strains based
on their 16S rRNA sequence in seven variable regions (V3–
V9). Twenty-six probes detect specific species, 19 probes
detect bacteria on the genus level, and 9 probes detect bacte-
ria at higher taxonomic levels. The signal detection was
performed by using a BioCode 1000A 128-Plex Analyzer
(Applied BioCode, Santa Fe Springs, CA, USA) [46].
3. Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 7
(GraphPad Software, Inc.). Normal distribution of data was
tested using the D’Agostino-Pearson omnibus normality test.
Kruskal-Wallis with Dunn’s post hoc test was used to compare
uroguanylin immunoreactive cells density between the
controls and the patients before and after receiving FMT.
Paired t-test is used to compare between the IBS-SQ symptoms
and cell densities of the patients before and after receiving
FMT. Mann-Whitney U test was used to compare the gut
microbiota profiles of the patients before and after FMT to their
respective donors. Correlations were performed using Pear-
son’s test for parametric and Spearman’s test for nonparamet-
ric datasets. The data are presented as mean ± SEM values.
P < 0:05 are considered to be statistically significant.
4. Results
Twelve patients (4 females and 8 males, with age range of
20-44 years) completed the study after excluding four
patients due to withdrawal of the participation consent for
practical reasons (n = 1), failed intubation of the endoscope
during the gastroscopy session 3 weeks after FMT (n = 1),
positive stool culture for Clostridium difficile (n = 1), and
being diagnosed with functional dyspepsia (n = 1). Six
patients suffered from post infectious (PI) IBS and six had
idiopathic IBS. They completed the whole study by filling
out the questionnaires and delivered stools for microbiota
analysis on the same day of undergoing gastroscopy with
duodenal biopsies, i.e., the day of FMT, and after 3 weeks.
No change in lifestyle, diet, or use of any/new medications
has been registered during the study.
4.1. Symptom Questionnaires. The total scores for IBS-SSS
and IBS-SQ significantly improved as previously reported
[26]. The scores for IBS-SQ showed significant improve-
ments in several of its domains in both groups of IBS as
shown in Table 1.
4.2. Gastroscopy, Histopathology, Immunohistochemistry,
and Image Analysis. The duodenum of the patients was both
macroscopically and microscopically normal.
Uroguanylin immunoreactive cells were found in both
the villi (Figure 2) and crypts (Figure 3) of the duodenum,
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which is consistent with a previous publication [47], in both
controls and IBS patients. The staining in the villi was con-
centrated mainly in the cytoplasm of the epithelial cells. Uro-
guanylin immunoreactive cells in the crypts, identified as
enteroendocrine cells, were either basket- or flask-shaped [48].
At baseline, the densities of uroguanylin immunoreactive
cells were significantly lower in the villi (P < 0:0001) and
higher in the crypts (P < 0:0001) for the patients than the
controls (Figures 4(a) and 4(b), respectively). Three weeks
after FMT, the densities of uroguanylin immunoreactive cells
for the total group and idiopathic IBS subgroup decreased
significantly in the duodenal crypts (P = 0:049 and 0.04,
respectively) but not in the villi (P = 0:5 and 0.8, respectively,
Table 2). No significant changes were shown in either duode-
nal crypt or villi in the PI-IBS subgroups, Table 2.
4.3. Gut Microbiota. The total changes occurring to the gut
microbiota profiles for the donors and the total group of IBS
patients before and after FMT were previously described [26,
28]. Briefly, several strains of the gut microbiota, namely, Rumi-
nococcus gnavus, Clostridium sensu stricto, Actinobacteria,
Bifidobacteria, and Gardnerella, for the donors were statisti-
cally significantly different from those for the patients before
FMT, which normalized for the patients 3 weeks after FMT.
No statistically significant differences were found in the bacte-
rial strains when comparing the patients before vs. after FMT.
4.4. Correlations.Using Pearson’s test, uroguanylin immuno-
reactive cells density before FMT correlated positively with
diarrhea (r = 0:97, P = 0:001) and negatively with bloating
(r = −0:91, P = 0:01) in the PI-IBS subgroup (Figures 5(a)
(a) (b) (c)
Figure 2: Uroguanylin immunoreactive cells in the duodenal villi for patients with irritable bowel syndrome before (a) and after (b) fecal
microbiota transplantation and controls (c).
(a) (b) (c)
Figure 3: Uroguanylin immunoreactive cells in the duodenal crypts for patients with irritable bowel syndrome before (a) and after (b) fecal
microbiota transplantation and controls (c).
Table 1: Scores of the irritable bowel syndrome-symptom questionnaire in post infectious and idiopathic irritable bowel syndrome before






Before FMT 3weeks after FMT Before FMT 3weeks after FMT
Nausea 2 ± 0:7 1 ± 0:6 0.2 5:3 ± 1:4 1:8 ± 0:98 0.002
Bloating 7:8 ± 0:5 3 ± 1:2 0.004 8 ± 1 3:8 ± 1:3 0.003
Abdominal pain 6:3 ± 1:4 4:3 ± 1:2 0.13 6:2 ± 1:2 2:2 ± 1 0.003
Constipation 2:7 ± 0:95 1:2 ± 0:8 0.3 5:8 ± 1:9 1:8 ± 1:2 0.1
Diarrhea 5:5 ± 1:5 1:2 ± 0:6 0.01 7:3 ± 0:95 1:2 ± 0:5 0.001
Anorexia 1 ± 0:5 1 ± 0:5 >0.99 3:5 ± 1:2 0:8 ± 0:5 0.038
Comparison: Paired t-test. Data are presented as themean ± SEM. ∗Post infectious IBS before vs. after FMT, ∗∗idiopathic IBS before vs. after FMT. FMT: fecal
microbiota transplantation; IBS-SQ: irritable bowel syndrome-symptom questionnaire.
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and 5(b), respectively). After FMT, uroguanylin cells densi-
tycorrelated positively with abdominal pain (r = 0:63, P =
0:03) in the total group of IBS patients (Figure 5(c)). No
correlations were found between the cells in the villi and
IBS symptoms.
Using Spearman’s correlation test, significant correla-
tions were found between several bacterial strains and uro-
guanylin immunoreactive cells density in the duodenal villi
and crypts of patients in the total group of IBS patients before
and after FMT as shown in Table 3. These cells density also
correlated with Bacteroides fragilis and Escherichia/Shigella
in the duodenal villi and crypts, respectively, before FMT in
the PI-IBS group. No correlations were found between the uro-
guanylin immunoreactive cells density and gut microbiota in
the idiopathic IBS group. The gut microbiota profiles that
correlated with the uroguanylin immunoreactive cells den-
sity are shown in Table 3.
5. Discussion
The current study describes the differences in the uroguany-
lin immunoreactive cells density between IBS-D patients and
controls. We also investigate how the cells density changes
following FMT and correlates to IBS symptoms and gut
microbiota before and after FMT.
Gut hormones, which control several functions of the
gastrointestinal tract [49, 50], are released by the enteroendo-
crine cells of the gut for which alterations in the densities of
these cells have also been postulated to play an important role
in the pathophysiology of IBS [29, 51–55]. To our knowledge,
the differences in the uroguanylin immunoreactive cells den-
sity between patients with IBS-D and controls have never
been described before. Significant differences in the densities
of uroguanylin immunoreactive cells were found between
IBS-D patients and controls at baseline, and only the density
of the cells in the crypts significantly changed following FMT.
It is difficult to explain why the changes in the density of uro-
guanylin immunoreactive cells were specific only to those in
the crypts following FMT; however, one may speculate that
the cells in the villi may react to different stimuli than those
they were exposed to in the current study.
Uroguanylin belongs to the guanylin peptide family that
serves as a paracrine/endocrine hormone and acts as ago-
nists of the guanylyl cyclase receptor GC-C, which regulates
intestinal electrolyte and water transport [30, 35]. The acti-
vation of these receptors by the small heat-stable entero-
toxins produced by the enterotoxigenic Escherichia coli
causes an increase in chloride ion secretion, leading to
secretory diarrhea [56, 57]. This explains the correlations
between uroguanylin immunoreactive cells density and
diarrhea in PI-IBS patients at baseline before FMT. Correla-
tions between uroguanylin and other IBS symptoms such as
bloating and abdominal pain are most probably due to the
same mechanism of the GC-C and cGMP pathway activation
leading to reduced visceral hypersensitivity [58, 59], thus link-
ing it to the gut-brain axis. Plecanatide®, a medication struc-
turally related to uroguanylin, has newly been introduced to
themarket for the treatment of abdominal pain and constipa-
tion in patients with constipation-predominant IBS [60].
Currently, no data is present to explain the correlations
between uroguanylin cells and other bacterial strains other
than those that produce small heat-stable-like toxins (other
Escherichia coli species, Yersinia enterocolitica, Vibrio cho-
lerae, Salmonella species, and Klebsiella pneumoniae) [61].
However, Bacteroides fragilis, which correlates with uroguanylin


























































Figure 4: Uroguanylin immunoreactive cells densities in the duodenal (a) villi and (b) crypts, for patients with irritable bowel syndrome and
controls.
Table 2: Densities of uroguanylin immunoreactive cells in the
duodenum of patients with irritable bowel syndrome before and




Before FMT After FMT P value
Total IBS group
Villi (cells/100 epithelial cells) 44 ± 5:5 41 ± 2:3 0.5
Crypts (cells/mm2) 116 ± 8 96 ± 3 0.049
PI-IBS
Villi (cells/100 epithelial cells) 45:8 ± 7:4 40:5 ± 3:3 0.6
Crypts (cells/mm2) 108 ± 11:8 102:5 ± 4 0.6
Idiopathic IBS
Villi (cells/100 epithelial cells) 42:5 ± 8:8 40:7 ± 3:6 0.8
Crypts (cells/mm2) 124 ± 11 89:5 ± 4 0.04
Comparison: Paired t-test. Data are presented as the mean ± SEM. IBS:
irritable bowel syndrome; PI: post infectious.
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by proteolytic degradation of tight junction proteins using
enterotoxin or fragilysin leading to diarrhea [61]. This toxin
is more potent when it acts on the basolateral rather than
the apical part of the epithelial surface [62].
The relationship between uroguanylin and guanylin and
their receptor is not limited to gastrointestinal disorders but
also involves renal disorders, colorectal cancer, metabolic
syndrome, and mental disorders among others [39]. Recent
studies identified a novel role for uroguanylin in obesity by
regulating satiety via the gut-brain axis [47].
The current study has several limitations such as the
small number of the participants and the lack of a placebo-
controlled group from which tissue biopsies could have been
taken from. For this exploratory and explanatory study, we
aimed to study if there were any differences in the uroguany-
lin enteroendocrine cells between the different subgroups of
IBS-D patients. Despite the small sample size of the different
IBS-D subgroups, we found significant differences in urogua-
nylin immunoreactive cells density before and after FMT;
however, further studies with larger groups of participants
are required to be able to draw firm conclusions.
6. Conclusions
Altered uroguanylin immunoreactive cells density has been
found in IBS-D patients compared to controls. Changes in
these cells density following FMT correlated with IBS symp-
toms (diarrhea, bloating, and abdominal pain). The current
study shows that both gut microbiota and the enteroendocrine
cells play an important role in the pathophysiology of IBS.
Data Availability
“All the data concerning uroguanylin immunoreactive cells
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So the data used to support the findings of this study are
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doi: 10.1371/journal.pone.0194904.s00.
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Figure 5: Correlations between scores of irritable bowel syndrome-symptom questionnaire (IBS-SQ) for (a) diarrhea, (b) bloating, and (c)
abdominal pain, and uroguanylin (UGN) immunoreactive cells density of the crypt in post infectious (PI-IBS) and total group of patients
with irritable bowel syndrome before and after fecal microbiota transplantation (FMT).
Table 3: Gut microbiota profiles that correlated with uroguanylin immunoreactive cells density in the duodenal villi and crypts of patients





cells density (r, P∗∗)
Before FMT After FMT Before FMT After FMT
Total IBS group
Bacteroides fragilis 39 ± 23 37 ± 16 0.72 Crypts (-0.81, 0.02) —
Parabacteroides 7:9 ± 3 14:6 ± 5 0.24 — Crypts (0.796, 0.01)
Alistipes 107 ± 25 127 ± 27 0.2 — Crypts (0.71, 0.038)
Streptococcus sanguinis and S. thermophilus 171 ± 80 78 ± 42 0.59 — Villi (0.69, 0.047)
PI-IBS group
Bacteroides fragilis 65 ± 26 36 ± 28 0.4 Villi (0.94, 0.02) —
Escherichia/Shigella 141 ± 104 181 ± 135 0.4 Crypts (0.94, 0.02) —
Comparison: Paired t-test. Data are presented as the mean ± SEM. Spearman’s correlation test (r) was used to correlate between the bacterial strain and
uroguanylin immunoreactive cells density in the duodenal villi and crypts. ∗Comparison between the signals before and after FMT; ∗∗P values for
correlations. FMT: fecal microbiota transplantation; IBS: irritable bowel syndrome; PI: post infectious.
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